Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 601 followers
Latest posts
Last updated 4 days ago
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma
4 days ago
As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep...
GSK completes acquisition of 35Pharma Inc.
9 days ago
GSK today announced the completion of its previously announced acquisition of 35Pharma...
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers
12 days ago
Promising efficacy and safety profile supports start of five pivotal phase III...
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)
16 days ago
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
25 days ago
Submission supported by statistically significant and clinically meaningful functional cure rates in...
Exdensur (depemokimab) approved in China for the treatment of severe asthma
25 days ago
Exdensur is the first and only ultra-long-acting biologic in China for the...
Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B
28 days ago
Submission supported by statistically significant and clinically meaningful functional cure rates in...
GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan
about 1 month ago
Designation supported by early clinical data showing durable responses in certain types...
Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
about 1 month ago
Approval based on the positive GLISTEN phase III trial with regulatory reviews...
GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk
about 1 month ago
In the US, an estimated 21 million adults under 50 have at...
GSK tops Antimicrobial Resistance (AMR) Benchmark Report
about 2 months ago
GSK welcomes independent recognition of our leadership in addressing the urgent global...
GSK and Alfasigma announce agreement on worldwide rights for linerixibat
about 2 months ago
GSK and Alfasigma today announced a licence agreement under which Alfasigma will...